Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. sophomore Avg
|
New words:
ablation, absorb, allogeneic, AMI, andDeclomycin, andHerceptin, andHuZAFin, andIsmo, andNuvion, andRaptiva, andRetavase, Andrew, andTysabri, andZamyl, andZenapax, anniversary, APIC, attend, automatic, automatically, awaiting, behavior, bioequivalent, blocker, bone, busulfan, cardiovascular, chemotherapeutic, chronic, CODM, component, coverCardene, creation, Deduct, deposited, dihydropyridine, discretion, dividend, dosage, employment, eradicate, ESPP, expansion, exposed, factor, forCardene, forecast, formulation, forNuvion, forNuvionfor, forRetavase, fromCardene, fromRetavase, FSP, graft, Guggenhime, hematopoietic, IfCardene, immaterial, immunosuppression, implied, includingAvastin, influenced, input, intensive, intravenously, intrinsic, introduced, itsXolair, IVBusulfex, joined, lesser, letter, leukemia, malignancy, manufactureRetavase, marginal, marrow, minimal, monoclonal, monthly, mortality, mouse, neurological, nonpatent, Nonstatutory, nonvested, obsolescence, ofAvastin, ofCardene, ofCardeneIV, ofDeclomycin, ofDeclomycinin, ofHerceptin, ofNuvion, ofRetavase, ofTysabri, ofTysabriprior, ofTysabrito, ofZenapax, onceZenapax, orRetavase, overstocking, paragraph, parent, Plc, pool, proceeding, productRetavase, progenitor, Reddy, refurbish, regimen, removed, requisite, residual, resubmitted, schedule, scheduled, sellingTysabri, simplified, space, statutory, stem, stream, supervision, Synagisand, thatNuvion, thatTysabri, toCardene, toDeclomycin, toDeclomycinand, toRetavase, toRetavaseincluded, ultimately, uncontested, unrecognized, ventricular, voluntary, weighted, whichCardene, whichRetavase, withTNKase™andActivase, written, wrote, yield
Removed:
abandoned, abandoning, abandonment, accurate, Acquirer, Activase, active, ads, advisory, affinity, amortized, animal, assumption, back, basiliximab, binding, Bulletin, CBER, CDER, Center, centralize, climate, communicate, compound, confidence, confirmed, consummated, contingency, contra, core, coupled, Declomycin, decrease, designated, dictate, discounted, discussed, distract, distribute, efficiency, EITF, endpoint, evaluating, execution, extension, goal, guaranteed, humanize, humanizing, HuZAF, III, illustrate, implemented, incompatibility, initiative, involvement, Ismo, issuable, journal, kidney, lacked, largely, launch, launched, leader, lease, leased, logo, media, month, nonmonetary, Nonrefundable, Nuvion, obligated, owe, panel, par, payable, preferred, present, preserving, prevention, Productive, productivity, project, projection, protein, provision, Raptiva, reclassify, reclassifying, recoverable, redeemed, reliably, remained, reteplase, reversion, revert, SAB, SEC, Sectral, semiannually, Showing, Simulect, single, speaker, stated, sublease, sustainable, target, Tenex, timeline, TNKase, trademark, Tysabri, variation, viability, workforce
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Offer Letter Between the Company and MR. Andrew L. Guggenhime
- 31.1 Certification of Principal Executive Officer Pursuant to Rule 13A-14(A)
- 31.2 Certification of Principal Financial Officer Pursuant to Rule 13A-14(A)
- 32.1 Certification by the CEO & CFO of PDL Biopharma, Inc.
Related press release
PDLI similar filings
Filing view
External links